



Discover QIAGEN®'s Sample to Insight®
GeneReader™ NGS System workflow for clinical
research insights at **AMP Global in Berlin April 3rd-5th**

- Visit us at booth 26a and find out what our Sample to Insight solutions could do for your lab.

- Join our Industry workshop

Time and date: April 5th 2017, 15:15-16:15

Location: Room 1

Program: GeneReader: a complete NGS System for Your Lab, Live in 30 Days

Kai te Kaat, Vice President Head of Franchise Oncology, Oncology Franchise, QIAGEN

Application of the GeneReader NGS System in Analyzing a Diverse Set of Cancer Clinical Samples

Dr Lisa Oberauner-Wappis, CBmed Graz, Center for Biomarker Research in Medicine, Graz, Austria

Detecting cancer mutations in liquid biopsy samples with NGS at high sensitivity and accuracy

Dr Clara Mayo de las Casas, Pangaea Oncology, Barcelona, Spain

- Discuss recent studies and their outcome at the poster sessions

Tuesday 4th April 10:00-11:00 – 3 posters

OTH01; Category: Other

Application of the GeneReader NGS System in Analyzing a Diverse Set of Cancer Clinical Samples

Lisa Oberauer-Wappis^{1,2}, Martina Loibner^{1,2}, Christine Ulz^{1,2}, Peter Abuja^{1,2}, Daniel Grözl³, Tomasz Krenz³, Georg Wiecek³, Uwe Oelmüller³, Kurt Zatloukal²

1. CBmed Graz, Center for Biomarker Research in Medicine, Graz, Austria; 2. Institute of Pathology, Medical University of Graz, Graz, Austria; 3. PreAnalytix GmbH, Hombrechtikon, Switzerland

Assessment of the GeneReader NGS System as a future clinical diagnostics tool. Colon cancer and melanoma FFPE fixed tissue and plasma samples were analyzed on the full workflow, including integrated bioinformatics analysis.

ST19; Category: Solid tumors

Detection and Classification of Clinical Tumor Variants Using the QIAGEN GeneReader NGS System

Scott A Turner, Hou-Sung Jung, Francine B Abreu, Jason D. Peterson, Gregory J Tsongalis

Laboratory for Clinical Genomics and Advanced Technologies (CGAT), Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USA

A performance comparison of the QIAGEN GeneReader NGS System and GeneRead™ QIAact Actionable Insights Tumor Panel, with the Ion PGM and Ion AmpliSeq™ Cancer Hotspot Panel v2 using a range of FFPE solid tumor samples.

ST21; Category: Solid tumors

Using GeneReader NGS System to Identify Germline and Somatic Mutations in BRCA 1/2 Genes

Olivier Biglia, Sophie Ravet, Pernelle Outters, Virginie Ahouansou, Leif Schausser, Simon Hughes, Dietrich Lueerssen, Yi Kong, Salim Essakali, Thomas Rothmann
QIAGEN GmbH, Hilden, Germany

The GeneRead QIAact BRCA 1/2 panel is the latest targeted gene panel to be released by QIAGEN for use with the GeneReader NGS System. The data presented here demonstrate the application of this panel as part of a complete Sample to Insight workflow to identify BRCA1/2 mutations in a set of clinical cancer samples.

Find out more about the GeneReader complete Sample to Insight workflow at www.qiagen.com/genereader

The GeneReader NGS System is for Research Use Only. Not for use in diagnostic procedures.

Trademarks: QIAGEN®, Sample to Insight® QIAact® (QIAGEN Group), QIAGEN GeneReader™, GeneReader™ (Intelligent Bio-Systems, Inc.), AmpliSeq™ (Life Technologies Corporation), Ion PGM™ (Life Technologies Corporation) Horizon®. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

© 2017 QIAGEN, all rights reserved. 03/2017 PROM-10647-001

Wednesday 5th April 10:00-11:00 – 3 posters

ST20; Category: Solid tumors

Application of Liquid Biopsy to Uncover Critical Cancer Insights Using the GeneReader NGS System

Luisa Andruzzi, Ben McNally, Angela DeLucia, Dona Hevroni, Leif Schausser, Vikas Gupta, Farrah Winterbottom, Dietrich Lueerssen, Simon Hughes, Yi Kong, Simone Guenther, Thomas Rothmann

QIAGEN GmbH, Hilden, Germany

Liquid Biopsy (LB) holds great promise as a non-invasive tumor sampling method, with the potential to provide real-time mutational information of a cancer. This poster presents the findings of an analysis of LB tumor samples, from sample preparation with QIAGEN's QIAamp® Circulating Nucleic Acid Kit, to sequencing and analysis on the QIAGEN GeneReader NGS System.

TT10; Category: Technical topics

A full Process Control for Setting up an NGS Operation Using the GeneReader System

Agus Darwanto, Farrah Winterbottom, Dietrich Lueerssen, Yi Kong, Simon Hughes, Hans Attig, Leif Schausser, Thomas Rothmann

QIAGEN GmbH, Hilden, Germany

A study applying the complete GeneReader NGS System and GeneRead QIAact Actionable Insights Tumor panel to a set of FFPE standards of known allelic frequency, produced by Horizon®. This poster also presents the incorporation of these standards into the GeneReader workflow as a full process control.

TT12; Category: Technical topics

Liquid biopsy: EGFR mutation testing using cell-free DNA and the GeneReader Workflow in a cohort of patients with advanced EGFR-mutant NSCLC

Seitz J¹, Moskalev EA¹, Fuchs F², Haller F¹

1 Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg

2 Department of Medicine, Pneumology, Friedrich-Alexander University of Erlangen-Nuremberg

Liquid biopsy (LB) has the potential to provide a minimally invasive alternative of tissue biopsy. Presented here is an evaluation of EGFR mutation detection from LB samples using the GeneRead QIAact Actionable Insights Tumor Panel with the LB workflow on the GeneReader NGS System.